Drug Trial Radar · NCT00045955
Long-Term Safety Performance of Fexofenadine in Asthma
Last checked: Nov 19, 2026Latest source record: Aug 21, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Planned (sponsor's estimate)
Start
Feb 2002
Primary completion
Nov 2003
Study completion Nov 2003
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma
Conditions
- Asthma
Interventions
Fexofenadine, Comparator = MontelukastDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aventis Pharmaceutical Inc.
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.